Davenport & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Davenport & Co’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$651K	Buy	19,500 +2,000	+11%	+$49.7K	﹤0.01%	909
2026 Q1	$367K	Buy	+17,500	New	+$394K	﹤0.01%	1052
2022 Q3	–	Sell	-5,782	Closed	-$345K	–	1023
2022 Q2	$345K	Buy	5,782 +456	+9%	+$28.1K	﹤0.01%	780
2022 Q1	$387K	Buy	5,326 +1,135	+27%	+$79K	﹤0.01%	802
2021 Q4	$352K	Buy	4,191 +56	+1%	+$4.56K	﹤0.01%	856
2021 Q3	$373K	Buy	4,135 +883	+27%	+$79.8K	﹤0.01%	794
2021 Q2	$310K	Buy	+3,252	New	+$339K	﹤0.01%	775

Other funds holding RARE

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return